BioInnovation Capital

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 55
Average round size
info
The average size of a deal this fund participated in
$37M
Portfolio companies 49
Rounds per year 11.00
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.11
Exits 12
Key employees 6
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

The venture was found in North America in United States. The main office of represented VC is situated in the Cambridge.

Among the most successful fund investment fields, there are Biotechnology, Medical Device. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight GraphWear Technologies, QurAlis, Cereius. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund.

The fund is constantly included in 2-6 deals per year. The common things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 23 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2019.

Besides them, we counted 6 critical employees of this fund in our database.

The standard case for the fund is to invest in rounds with 3 partakers. Despite the BioInnovation Capital, startups are often financed by [email protected], North Carolina Biotechnology Center, National Science Foundation. The meaningful sponsors for the fund in investment in the same round are Canaan Partners, Viva BioInnovator, The Engine.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of BioInnovation Capital:
Typical Co-investors
BioInnovation Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after BioInnovation Capital:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Nuvig Therapeutics

Therapeutics
$47M11 May 2022 Redwood City, California, United States

Arkuda Therapeutics

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$64M10 Feb 2022 Cambridge, Massachusetts, United States

AmbAgon Therapeutics

Biotechnology
Medical
Product Research
$85M06 Jan 2022 San Francisco, California, United States

Tune Therapeutics

Biotechnology
$40M02 Dec 2021 Seattle, Washington, United States

GraphWear Technologies

Application Software
Health Care
Medical Device
Monitoring Equipment
Nanotechnology
Other Healthcare Technology Systems
$20M05 Oct 2021 San Francisco, California, United States

Asher Bio

Biotechnology
Therapeutics
$108M01 Sep 2021 San Francisco, California, United States

Shape Therapeutics

Biotechnology
$112M15 Jul 2021 Seattle, Washington, United States

Glycomine

Biotechnology
Pharmaceutical
Therapeutics
$35M23 Jun 2021 San Francisco, California, United States

Vedere Bio

Biotechnology
Health Care
Therapeutics
$77M18 May 2021 Cambridge, Massachusetts, United States
News
Asher Bio Closes $108 Million Series B Financing

– Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the closing of an oversubscribed Series B financing, which raised $108m.
– The financing was led by Wellington Management Company, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace and Alexandria Venture Investments, and, along with existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and other undisclosed institutional investors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent BioInnovation Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: